The MoCA: well-suited screen for cognitive impairment in Parkinson disease JC Dalrymple-Alford, MR MacAskill, CT Nakas, L Livingston, C Graham, ... Neurology 75 (19), 1717-1725, 2010 | 1001 | 2010 |
The genetic architecture of the human cerebral cortex KL Grasby, N Jahanshad, JN Painter, L Colodro-Conde, J Bralten, ... Science 367 (6484), eaay6690, 2020 | 660 | 2020 |
Grey matter atrophy in cognitively impaired Parkinson's disease TR Melzer, R Watts, MR MacAskill, TL Pitcher, L Livingston, RJ Keenan, ... Journal of Neurology, Neurosurgery & Psychiatry 83 (2), 188-194, 2012 | 325 | 2012 |
General functional connectivity: Shared features of resting-state and task fMRI drive reliable and heritable individual differences in functional brain networks ML Elliott, AR Knodt, M Cooke, MJ Kim, TR Melzer, R Keenan, D Ireland, ... NeuroImage 189, 516-532, 2019 | 279 | 2019 |
Brain-age in midlife is associated with accelerated biological aging and cognitive decline in a longitudinal birth cohort ML Elliott, DW Belsky, AR Knodt, D Ireland, TR Melzer, R Poulton, ... Molecular psychiatry 26 (8), 3829-3838, 2021 | 219 | 2021 |
Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson’s disease TR Melzer, R Watts, MR MacAskill, JF Pearson, S Rüeger, TL Pitcher, ... Brain 134 (3), 845-855, 2011 | 209 | 2011 |
Characterizing mild cognitive impairment in Parkinson's disease JC Dalrymple‐Alford, L Livingston, MR MacAskill, C Graham, TR Melzer, ... Movement Disorders 26 (4), 629-636, 2011 | 193 | 2011 |
Disparities in the pace of biological aging among midlife adults of the same chronological age have implications for future frailty risk and policy ML Elliott, A Caspi, RM Houts, A Ambler, JM Broadbent, RJ Hancox, ... Nature aging 1 (3), 295-308, 2021 | 185 | 2021 |
White matter microstructure deteriorates across cognitive stages in Parkinson disease TR Melzer, R Watts, MR MacAskill, TL Pitcher, L Livingston, RJ Keenan, ... Neurology 80 (20), 1841-1849, 2013 | 181 | 2013 |
Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis L Debernard, TR Melzer, S Van Stockum, C Graham, ... Journal of Neurology, Neurosurgery & Psychiatry 85 (5), 544-551, 2014 | 114 | 2014 |
Bio-medical X-ray imaging with spectroscopic pixel detectors APH Butler, NG Anderson, R Tipples, N Cook, R Watts, J Meyer, AJ Bell, ... Nuclear Instruments and Methods in Physics Research Section A: Accelerators …, 2008 | 110 | 2008 |
Comparing cerebral perfusion in Alzheimer's disease and Parkinson's disease dementia: an ASL-MRI study CJL Heron, SL Wright, TR Melzer, DJ Myall, MR MacAskill, L Livingston, ... Journal of Cerebral Blood Flow & Metabolism 34 (6), 964-970, 2014 | 89 | 2014 |
Pervasively thinner neocortex as a transdiagnostic feature of general psychopathology AL Romer, ML Elliott, AR Knodt, ML Sison, D Ireland, R Houts, ... American Journal of Psychiatry 178 (2), 174-182, 2021 | 83 | 2021 |
Different PD-MCI criteria and risk of dementia in Parkinson’s disease: 4-year longitudinal study KL Wood, DJ Myall, L Livingston, TR Melzer, TL Pitcher, MR MacAskill, ... npj Parkinson's Disease 2 (1), 1-8, 2016 | 83 | 2016 |
Associations between life-course-persistent antisocial behaviour and brain structure in a population-representative longitudinal birth cohort CO Carlisi, TE Moffitt, AR Knodt, H Harrington, D Ireland, TR Melzer, ... The Lancet Psychiatry 7 (3), 245-253, 2020 | 82 | 2020 |
Deep grey matter MRI abnormalities and cognitive function in relapsing-remitting multiple sclerosis L Debernard, TR Melzer, S Alla, J Eagle, S Van Stockum, C Graham, ... Psychiatry Research: Neuroimaging 234 (3), 352-361, 2015 | 77 | 2015 |
International multicenter analysis of brain structure across clinical stages of Parkinson's disease MA Laansma, JK Bright, S Al‐Bachari, TJ Anderson, T Ard, F Assogna, ... Movement disorders 36 (11), 2583-2594, 2021 | 76 | 2021 |
Longitudinal in vivo monitoring of the CNS demonstrates the efficacy of gene therapy in a sheep model of CLN5 Batten disease NL Mitchell, KN Russell, MP Wellby, HE Wicky, L Schoderboeck, ... Molecular Therapy 26 (10), 2366-2378, 2018 | 75 | 2018 |
Beta amyloid deposition is not associated with cognitive impairment in Parkinson's disease TR Melzer, MR Stark, RJ Keenan, DJ Myall, MR MacAskill, TL Pitcher, ... Frontiers in neurology 10, 391, 2019 | 71 | 2019 |
White matter hyperintensities are common in midlife and already associated with cognitive decline T d’Arbeloff, ML Elliott, AR Knodt, TR Melzer, R Keenan, D Ireland, ... Brain Communications 1 (1), fcz041, 2019 | 70 | 2019 |